Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells

Peralta-Garcia, Alejandro; Torrens-Fontanals, Mariona; Stepniewski, Tomasz Maciej; Grau Exposito, Judit; Perea Pérez, David; Ayinampudi, Vikram; Buzón Gómez, María José; Genesca Ferrer, Meritxell

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Peralta-Garcia, Alejandro
dc.contributor.author	Torrens-Fontanals, Mariona
dc.contributor.author	Stepniewski, Tomasz Maciej
dc.contributor.author	Grau Exposito, Judit
dc.contributor.author	Perea Pérez, David
dc.contributor.author	Ayinampudi, Vikram
dc.contributor.author	Buzón Gómez, María José
dc.contributor.author	Genesca Ferrer, Meritxell
dc.date.accessioned	2022-06-15T11:45:19Z
dc.date.available	2022-06-15T11:45:19Z
dc.date.issued	2021-12
dc.identifier.citation	Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592.
dc.identifier.issn	1422-0067
dc.identifier.uri	https://hdl.handle.net/11351/7684
dc.description	COVID-19; Drug repurposing; Viral cell entry assays
dc.description.abstract	Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug.
dc.language.iso	eng
dc.publisher	MDPI
dc.relation.ispartofseries	International Journal of Molecular Sciences;22(24)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Medicaments antivírics
dc.subject	COVID-19 (Malaltia)
dc.subject	Medicaments - Ús
dc.subject.mesh	Antiviral Agents
dc.subject.mesh	/pharmacology
dc.subject.mesh	Drug Repositioning
dc.subject.mesh	Coronavirus Infections
dc.title	Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.3390/ijms222413592
dc.subject.decs	antivíricos
dc.subject.decs	/farmacología
dc.subject.decs	nuevas indicaciones de medicamentos
dc.subject.decs	infecciones por Coronavirus
dc.relation.publishversion	https://doi.org/10.3390/ijms222413592
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Peralta-Garcia A, Torrens-Fontanals M] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. [Stepniewski TM] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland. [Grau-Expósito J, Perea D, Buzón MJ, Genescà M] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ayinampudi V] InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland
dc.identifier.pmid	34948390
dc.identifier.wos	000737887800001
dc.rights.accessrights	info:eu-repo/semantics/openAccess